Destiny Pharma Stock Quote DEST - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

3.00

Bid

2.50

Ask

3.50

Volume

0.00

0.00 Day's Range 0.00

2.25 52 Week Range 83.00

Market Cap

2.873M

Previous Close

3.00

Open

Last Trade

(O)

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

1,446,789

Shares Outstanding

95,770,611

Dividend Yield

PE Ratio

-0.51

Earnings Per Share (EPS)

-0.06

Revenue

832k

Net Profit

-5.66M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.destinypharma.com

Headquarters

Brighton & Hove, Gbr

Founded

Destiny Pharma Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker DEST. The last closing price for Destiny Pharma was 3p. Over the last year, Destiny Pharma shares have traded in a share price range of 2.25p to 83.00p.

Destiny Pharma currently has 95,770,611 shares outstanding. The market capitalization of Destiny Pharma is £2.87 million. Destiny Pharma has a price to earnings ratio (PE ratio) of -0.51.

AIM Cancellation - Destiny Pharma plc

AIM 13 August 2024 NOTICE 13/08/2024 - 07:00 NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON AIM At the request of the company the following securities have been cancelled from...

Destiny Pharma PLC Last Day of Dealings on AIM

Destiny Pharma PLC 12 August 2024 Destiny Pharma plc ("Destiny Pharma" or "the Company") Last Day of Dealings on AIM Brighton, United Kingdom - 12 August 2024 - Destiny Pharma plc (AIM:...

Destiny Pharma PLC Director/PDMR Shareholding

Destiny Pharma PLC 05 August 2024 Destiny Pharma plc ("Destiny Pharma" or "the Company") Director/PDMR Shareholding Brighton, United Kingdom - 5 August 2024 - Destiny Pharma plc (AIM:...

Destiny Pharma shares fall amid XF-73 fending off MRSA in wounds

Destiny Pharma PLC on Monday announced positive data for its lead drug exeporfinium chloride, known as XF-73, and to ...

Destiny Pharma PLC XF-73 prevents bacterial invasion of bloodstream

Destiny Pharma PLC 05 August 2024 Destiny Pharma plc ("Destiny Pharma" or "the Company") XF-73 treatment of MRSA burn wound infection prevents bacterial invasion of the bloodstream Data...

Destiny Pharma PLC Result of GM and Cancellation of Trading on AIM

Destiny Pharma PLC 31 July 2024 Destiny Pharma plc ("Destiny Pharma" or "the Company") Result of General Meeting and Cancellation of Admission to Trading on AIM Brighton, United...

Destiny Pharma PLC Treatment of XF-73 Nasal reduces antibiotic use

Destiny Pharma PLC 22 July 2024 Destiny Pharma plc ("Destiny Pharma" or "the Company") Cardiac surgery patients treated with XF-73 Nasal gel require significantly fewer post-surgical...

Destiny Pharma looks to go private to raise funds, avoid liquidation

Destiny Pharma PLC on Monday proposed going private to pursue funding opportunities after failing to secure a licensi ...

Destiny Pharma PLC Proposed Cancellation of Admission to Trading

Destiny Pharma PLC 15 July 2024 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED...

Destiny Pharma PLC Exercise of Options and Total Voting Rights

Destiny Pharma PLC 20 June 2024 20 June 2024 Destiny Pharma plc ("Destiny Pharma" or the "Company") Exercise of Options and Total Voting Rights Brighton, United Kingdom - 20 June 2024 ...